{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:40:47Z","timestamp":1774395647545,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>We evaluated the combination of ATG and PTCy for GVHD prophylaxis in matched and mismatched unrelated PBSCTs for high\u2010risk hematological malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We treated 102 patients with reduced intensity conditioning (RIC) with fludarabine, busulfan, and TBI 200\u00a0cGy. GVHD prophylaxis included rabbit ATG (thymoglobulin at total dose of 4.5\u00a0mg\/kg divided over days \u22123 to \u22121), PTCy (50\u00a0mg\/kg\/day on day +3 and on day +4), and cyclosporine. Clinical and outcome data were collected retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 102 patients, 76 patients received 10\/10 MUD transplants and 26 patients received 9\/10 mismatched transplants. The median age was 59\u00a0years. At a median follow\u2010up of 15\u00a0months (range 0.6 to \u221233\u00a0months), the 1\u2010year OS in MUD and MMUD cohort was 75% and 50%, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.027). The corresponding one\u2010year PFS was 67% and 35%, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0024). The incidence of grade 3\u20104 acute GVHD was 11.8% in MUD and 3.8% in MMUD group, and that of NIH stage moderate\/severe chronic GVHD in the 2 groups was 10.5% and 7.6%, respectively. Cytomegalovirus (CMV) reactivation was seen in 49% patients. The cumulative incidence of relapse was 21.1% in the MUD group and 42.3% in the MMUD group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our experience shows that PTCy and ATG can be combined for GVHD prophylaxis in matched unrelated donor PBSCTs with low rates of Gr3\u20104 acute GVHD and chronic GVHD, and acceptable relapse rates.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13230","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T13:13:52Z","timestamp":1553865232000},"page":"486-493","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants"],"prefix":"10.1111","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-8306","authenticated-orcid":false,"given":"Shruti","family":"Prem","sequence":"first","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad","family":"Al\u2010Shaibani","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Loach","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Law","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-0848","authenticated-orcid":false,"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhosh","family":"Thyagu","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis (Dong Hwan)","family":"Kim","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Howard Lipton","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.034"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V126.23.1950.1950","article-title":"Use of post\u2010transplant cyclophosphamide (PTCy) with mycophenolate mofetil and tacrolimus in HLA matched allogeneic hematopoietic cell transplant is safe and associated with acceptable transplant outcomes","volume":"126","author":"Hess BT","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.81"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-438408"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.005"},{"key":"e_1_2_8_9_1","first-page":"1978","article-title":"Post\u2010transplant cyclophosphamide (PTCy) with anti\u2010thymocyte globulin (ATG) as Gvhd prophylaxis is effective in haploidentical peripheral stem cell transplantation and without increasing risk of relapse","volume":"130","author":"Lin CC","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood.V128.22.5871.5871","article-title":"Addition of ATG to myeloablative haplo conditioning with post\u2010transplantation cyclophosphamide might decrease the risk of Gvhd and TRM without increasing the risk of relapse","volume":"128","author":"Dawsari G","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V128.22.3430.3430","article-title":"Post\u2010transplant cyclophosphamide (PTCy) with anti\u2010thymocyte globulin (ATG) effectively reduces the severe (Grade III\u2010IV) acute graft\u2010versus\u2010host disease (GVHD) when compared to ATG alone in matched unrelated donor (MUD) allogeneic hematopoietic cell transplants","volume":"128","author":"Deotare U","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0053-9"},{"key":"e_1_2_8_14_1","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.149427"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00462-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587477"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0625"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8428"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-672071"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single\u2010agent high\u2010dose cyclophosphamide for graft\u2010versus\u2010host disease prophylaxis in human leukocyte antigen\u2010matched reduced\u2010intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft\u2010versus\u2010host disease","volume":"21","author":"Bradstock KF","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12541"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.026"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.006"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144139"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4777"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.029"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506002"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24328"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2423-y"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.013"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12455"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13150"},{"key":"e_1_2_8_35_1","first-page":"1","article-title":"Post\u2010transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation","volume":"3","author":"Romero S","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1365860"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144428"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.02.367"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24342"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.04.010"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood.V124.21.2486.2486","article-title":"Transplant outcomes of 9\/10 HLA matched unrelated donors (MUD) treated with post\u2010transplant cyclophosphamide for prevention of graft versus host disease","volume":"124","author":"Pingali SR","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002766"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13977"},{"key":"e_1_2_8_44_1","first-page":"50","article-title":"Prognostic significance of residual acute myeloid leukemia in bone marrow samples taken prior to allogeneic hematopoietic cell transplantation","volume":"147","author":"Kovach AE","year":"2017","journal-title":"Am J Clin Pathol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:59:26Z","timestamp":1694343566000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/ejh.13230"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13230","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"2019-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}